Neuphoria Therapeutics Inc Total Assets
Neuphoria Therapeutics Inc total assets. Based on the latest financial reports, Neuphoria Therapeutics Inc (NEUP) holds total assets worth $28.71 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see NEUP market cap for the company's overall valuation and market capitalisation.
Total Assets of Neuphoria Therapeutics Inc (1999–2026)
Total assets of Neuphoria Therapeutics Inc from 1999 to 2026. This chart illustrates how Neuphoria Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Neuphoria Therapeutics Inc for real-time trading data and today's change.
Neuphoria Therapeutics Inc - Asset Composition Analysis
Neuphoria Therapeutics Inc Total Assets Breakdown (June 2026)
Neuphoria Therapeutics Inc total assets breakdown as of June 2026. Neuphoria Therapeutics Inc's total assets of $28.71 Million consist of 73.4% current assets and 26.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.2% |
| Accounts Receivable | $813.43K | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $4.14 Billion | 14.4% |
| Goodwill | $3.50 Billion | 12.2% |
Asset Composition Trend (1999–2026)
This chart illustrates how Neuphoria Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore NEUP net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Neuphoria Therapeutics Inc's current assets represent 73.4% of total assets in 2026, a decrease from 100.0% in 1999.
- Cash Position: Cash and equivalents constituted 69.2% of total assets in 2026, up from 40.4% in 1999.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 26.0% of total assets, an increase from 0.0% in 1999.
- Asset Diversification: The largest asset category is intangible assets at 14.4% of total assets.
Neuphoria Therapeutics Inc Competitors by Total Assets
Key competitors of Neuphoria Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Neuphoria Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 27.85 | 3.56 | 13.10 |
| Quick Ratio | 27.85 | 3.56 | 13.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $20.31 Million | $16.44 Million | $28.57 Million |
Neuphoria Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Neuphoria Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.81 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 65990.3% |
| Total Assets | $28.71 Billion |
| Market Capitalization | $16.18 Million USD |
Valuation Analysis
Below Book Valuation: The market values Neuphoria Therapeutics Inc's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Neuphoria Therapeutics Inc's assets grew by 65990.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Neuphoria Therapeutics Inc (1999–2026)
The table below shows the annual total assets of Neuphoria Therapeutics Inc from 1999 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-06-30 | $28.71 Billion | +65990.33% |
| 2025-06-30 | $43.44 Million | +57.11% |
| 2024-06-30 | $27.65 Million | +42.57% |
| 2023-06-30 | $19.39 Million | -70.30% |
| 2022-06-30 | $65.30 Million | +60.17% |
| 2021-06-30 | $40.77 Million | +72.17% |
| 2020-06-30 | $23.68 Million | -36.99% |
| 2019-06-30 | $37.58 Million | -21.38% |
| 2018-06-30 | $47.80 Million | -26.02% |
| 2017-06-30 | $64.61 Million | -1.70% |
| 2016-06-30 | $65.72 Million | +23.95% |
| 2015-06-30 | $53.02 Million | -13.44% |
| 2014-06-30 | $61.25 Million | +25.20% |
| 2013-06-30 | $48.93 Million | +53.71% |
| 2012-06-30 | $31.83 Million | -13.19% |
| 2011-06-30 | $36.67 Million | +36.91% |
| 2010-06-30 | $26.78 Million | +34.22% |
| 2009-06-30 | $19.95 Million | -26.34% |
| 2008-06-30 | $27.09 Million | +3.62% |
| 2007-06-30 | $26.14 Million | +78.69% |
| 2006-06-30 | $14.63 Million | +12.53% |
| 2005-06-30 | $13.00 Million | +24.28% |
| 2004-06-30 | $10.46 Million | +23.50% |
| 2003-06-30 | $8.47 Million | -5.01% |
| 2002-06-30 | $8.92 Million | +61.36% |
| 2001-06-30 | $5.53 Million | +74.38% |
| 2000-06-30 | $3.17 Million | +2128.83% |
| 1999-06-30 | $142.19K | -- |
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, develops novel allosteric ion channel modulators for patients with serious central nervous system disorders in Australia. Its lead product candidate is BNC210, an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor for post-traumatic stress disorder. The company also deve… Read more